Pyrovalerone
Aliases: O-2371, Centroton, Thymergix, 4-methyl-ฮฒ-keto-prolintane
Categories
Summary
Pyrovalerone was originally prescribed for chronic fatigue and obesity in the 1960s at daily doses of 60 mg (20 mg three times daily), but patients frequently developed tolerance and compulsive redosing, leading to discontinuation of its clinical use. Modern reports describe it as a stimulant with a profile between methylphenidate and MDPV, with strong drive to redose every 2-3 hours. Its pharmacology shows high affinity inhibition of dopamine and norepinephrine transporters, with negligible serotonin activity. The short half-life contributes to a sharp comedown marked by irritability, low mood, and insomnia. Accurate dosing is critical as pyrovalerone is active at low milligram amounts, making volumetric measurement safer than weighing single doses.
Dose Information
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | After Effects |
|---|---|---|---|---|---|
| Oral | 10-30 min | 30-60 min | 30 min | 1-3 hrs | 2-24 hrs |
| Insufflated | 5-10 min | 15-30 min | 30 min | 1-3 hrs | 2-24 hrs |
| Rectal | 10-20 min | 20-40 min | 30 min | 1-3 hrs | 2-24 hrs |
| Intravenous | 2 min | 2-5 min | 30 min | 1-3 hrs | 2-24 hrs |
Tolerance
Effects
- Stimulation
- Increased Energy
- Teeth grinding
- Increased heart rate
- Pupil Dilation
- Increased Heart Rate
- Jaw Tension
- Restlessness
- Teeth Grinding
- Difficulty Sleeping
- Motivation enhancement
- Euphoria
- Enhanced Sociability
- Motivation Enhancement
- Anxiety
- Compulsive redosing
- Irritability
- Depression
- Increased focus
- Talkativeness
- Increased libido
- Tactile enhancement
- Increased music appreciation
- Appetite suppression
- Light sensitivity
- Appetite Suppression
- Disinhibition
- Dehydration
- Vibrating vision
- Increase sexuality